MedicGo
Unpredicted late-, new-onset thrombocytopenia and hypofibrinogenemia in Fab antivenom-treated rattlesnake envenomation.
Metadata
Journaltoxicon2.201Date
2020 Jun 04
4 months ago
Type
Journal Article
Volume
2020-Sep / 184 : 55-56
Author
Seifert SA 1, Mascarenas DN 2, Fullerton L 2, Warrick BJ 3, Smolinske SC 4
Affiliation
  • 2. Division of Pediatric Emergency Medicine, Department of Emergency Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • 3. University of New Mexico Health Sciences Center, Department of Emergency Medicine, University of New Mexico Health Sciences Center, Albuquerque, NM, USA; New Mexico Poison Center, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
  • 4. New Mexico Poison Center, University of New Mexico Health Sciences Center, Albuquerque, NM, USA.
Doi
PMIDMESH
Afibrinogenemia
Animals
Antivenins
Crotalid Venoms
Crotalus
Humans
Immunoglobulin Fab Fragments
Sheep
Snake Bites
Thrombocytopenia
Abstract
The use of Fab antivenom (Crotalidae Polyvalent Immune Fab (Ovine) (CroFab); Boston Scientific) against North American Crotalidae envenomation is associated with the development of late- (≥4 days post-envenomation), new-onset of hematological abnormalities. Although attempts have been made to identify predictive indicators during the acute phase of an envenomation, of patients who are not at-risk of late-, new-onset of hematological abnormalities, there has been at least one prior report of a patient who developed thrombocytopenia that was unpredicted by current indicators. We add three cases of unpredicted, late-, new-onset of hematological abnormalities in patients with Fab-treated rattlesnake bite.
Keywords: Antivenom Envenomation Fab Fibrinogen Platelets Rattlesnake Recurrence
Fav
Like
Download
Share
Export
Cite
2.2
Toxicontoxicon
Metadata
LocationEngland
FromPERGAMON-ELSEVIER SCIENCE LTD

No Data

© 2017 - 2020 Medicgo
Powered by some medical students